Cardioprotective effects of erythropoietin in diabetic rats determined by CD34 and vascular endothelial growth factor levels.
cardioprotective effect mechanisms
diabetes mellitus
erythropoietin
Journal
Archives of medical sciences. Atherosclerotic diseases
ISSN: 2451-0629
Titre abrégé: Arch Med Sci Atheroscler Dis
Pays: Poland
ID NLM: 101701205
Informations de publication
Date de publication:
2020
2020
Historique:
received:
01
10
2019
accepted:
24
10
2019
entrez:
15
2
2021
pubmed:
16
2
2021
medline:
16
2
2021
Statut:
epublish
Résumé
In this study, the effects of diabetes mellitus on the cardiovascular system were investigated by assessing the stem cell levels in serum and heart and compared with the normal population. Additionally, efficacy of erythropoietin, which is known to increase stem cells, was studied in diabetic rats. Twenty-five male Sprague Dawley rats were divided into three groups as a control group (group 1), diabetic group (group 2) and erythropoietin induced diabetic group (group 3). A diabetes model was created with streptozocin. In group 3 rats received 3000 U/kg of erythropoietin. At the end of 1 month blood reticulocyte levels, degree of tissue fibrosis and immunohistochemical assessment of reliable stem cell markers, CD34 and vascular endothelial growth factor (VEGF), were analyzed. The increase in the blood glucose levels resulted in a significant decrease in reticulocyte levels in group 2. The increase in blood glucose levels resulted in a statistically significant increase in tissue level of fibrosis, CD34 and VEGF. When the rats in groups 1 and 2 were compared, the fibrosis, CD34 and VEGF levels were found to increase significantly. When group 2 and group 3 were compared, the amount of fibrosis was lower and the levels of CD34 and VEGF were significantly higher in group 3 than group 2. The results of our study indicated that the amount of CD34 and VEGF which function in cellular protection and tissue regeneration may be enhanced with safely applicable erythropoietin leading to increase in reticulocyte levels in serum, and CD34 and VEGF levels in right atrium, right ventricle, left atrium, and left ventricle as a protective mechanism in diabetic rats.
Identifiants
pubmed: 33585719
doi: 10.5114/amsad.2020.92346
pii: 39581
pmc: PMC7863553
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1-e12Informations de copyright
Copyright: © 2020 Termedia & Banach.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Nihon Rinsho. 2011 Jan;69(1):131-7
pubmed: 21226273
Blood. 1999 Apr 15;93(8):2627-36
pubmed: 10194442
Cardiovasc Diabetol. 2012 Sep 07;11:105
pubmed: 22954171
Int J Biol Macromol. 2019 Feb 15;123:494-499
pubmed: 30447355
Blood. 2004 Feb 1;103(3):921-6
pubmed: 14525788
Microvasc Res. 2009 May;77(3):370-6
pubmed: 19249320
J Cell Biochem. 2018 Jan;119(1):95-104
pubmed: 28543595
Thorac Cardiovasc Surg. 2009 Mar;57(2):63-73
pubmed: 19241306
Regen Med. 2013 May;8(3):351-60
pubmed: 23627828
J Cardiovasc Transl Res. 2012 Oct;5(5):713-26
pubmed: 22648235
Circulation. 1999 Sep 7;100(10):1134-46
pubmed: 10477542
Interact Cardiovasc Thorac Surg. 2009 Jul;9(1):20-5; discussion 25
pubmed: 19380336
Regen Med. 2013 Jul;8(4):453-66
pubmed: 23826699
J Surg Res. 2012 Jul;176(1):e47-55
pubmed: 22595018
J Cell Mol Med. 2009 Apr;13(4):664-79
pubmed: 19449462
Expert Opin Ther Targets. 2009 Mar;13(3):267-74
pubmed: 19236149
Cell Transplant. 2009;18(8):855-68
pubmed: 19500473
Postgrad Med J. 2016 Feb;92(1084):63-9
pubmed: 26621825